Please login to the form below

Acthar

This page shows the latest Acthar news and features for those working in and with pharma, biotech and healthcare.

Mallinckrodt files for bankruptcy protection in the US

In addition to resolving matters relating to the opioid litigation, the bankruptcy filing will also resolve matters related to Mallinckrodt’s Acthar (corticotropin) Gel. ... Mallinckrodt agreed to pay $260m over seven years to the federal government

Latest news

US piles pressure on Mallinckrodt over alleged Acthar fraud

system. The complainant says that Mallinckrodt understated the rebates it was due to pay Medicaid over a period in which it raised the price of its $40, 000-per-vial Acthar ... The NDA approval was awarded to Acthar’s earlier owner Questcor, which was
Mallinckrodt offloads CDMO for $250m

This will likely include the active ingredient for Acthar, which the pharma company has faced criticism for due to its inflated pricing. ... US health insurer Humana recently filed a lawsuit against Mallinckrodt, alleging that it overpaid $700m for Acthar
Humana lawsuit targets Mallinckrodt's 'billion-dollar golden goose'

The nonprofit allegedly used money from Mallinckrodt to provide patient assistance funds solely for Acthar. ... Over the decades, other drugs superseded Acthar in many, but not all, indications, culminating in Aventis Pharmaceuticals selling the asset to
Mallinckrodt pays $1.2bn for Sucampo Pharma

Mallinckrodt is trying to reduce its reliance on cash cow product Acthar (corticotropin) for infantile spasms and multiple sclerosis, which brought in sales of almost $309m in the third quarter of ... Acthar’s slowdown has been attributed by the
Ireland's Mallinckrodt buys US regenerative medicine firm

Ikaria. In the previous year it shelled out $5.6bn for Questcor Pharma - getting hold of fast-growing autoimmune and inflammatory drug Acthar (repository corticotropin injection) - and another $1.3bn for

More from news
Approximately 2 fully matching, plus 7 partially matching documents found.

Latest Intelligence

Deal Watch table for April 2014

7, 100. Questcor/ Mallinckrodt. Acquisition. Acthar Gel (repository corticotropin) for “difficult-to-treat” autoimmune/ inflammatory conditions.
Pharma deals during April 2014

This gives Mallinckrodt, Acthar Gel (repository corticotropin), which is FDA approved for 19 “difficult-to-treat” autoimmune and inflammatory associated conditions and currently primarily used to treat multiple sclerosis relapses, proteinuria
Pharma deals during February 2014

Questor and Retrophin are is now in litigation over two synthetic versions of Acthar (ACTH), a corticotropin with 19 indications, many in rare diseases including infantile spasms, MS, nephrology, and rheumatology.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

Questcor appoints SVP corporate strategic development

These moves could see it expand outside the US with its lead product HP Acthar Gel (repository corticotropin injection), an injectable drug, which is approved by the FDA in several indications ... Development programmes that complement Acthar are also